The supreme court changes biotech deal flow

被引：0

作者：

Warburg, RJ ^{[1
]}

机构：

[1] Foley & Lardner, San Diego, CA 92130 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2005年 / 15卷 / 12期

关键词：

generic drug; research tool; safe harbour; stem cell;

D O I：

10.1517/13543776.15.12.1783

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In the recent case of Integra LifeSciences vs. Merck KGaA, the US Supreme Court has provided a broad exemption to patent infringement that could change the way that deals are done in the biotech arena. Companies can now develop new drugs free from patent infringement. How do you now negotiate deals in light of this decision?.

引用

页码：1783 / 1785

页数：3